Shares of NuCana PLC (NASDAQ:NCNA) hit a new 52-week low on Thursday . The stock traded as low as $9.56 and last traded at $10.41, with a volume of 56600 shares trading hands. The stock had previously closed at $10.37.
NCNA has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded shares of NuCana from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research report on Tuesday. Cowen initiated coverage on shares of NuCana in a research report on Monday, October 23rd. They issued an “outperform” rating on the stock. William Blair initiated coverage on shares of NuCana in a research note on Monday, October 23rd. They issued an “outperform” rating for the company. Citigroup initiated coverage on shares of NuCana in a research note on Monday, October 23rd. They issued a “buy” rating and a $23.00 target price for the company. Finally, Jefferies Group initiated coverage on shares of NuCana in a research note on Monday, October 23rd. They issued a “buy” rating and a $25.00 target price for the company. Five analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average price target of $20.00.
The company has a market capitalization of $331.26 and a P/E ratio of -32.53.
WARNING: “NuCana (NCNA) Hits New 12-Month Low at $9.56” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.com-unik.info/2017/12/28/nucana-ncna-hits-new-12-month-low-at-9-56.html.
NuCana Company Profile
NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.
What are top analysts saying about NuCana? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for NuCana and related companies.